Major ADHD review maps biology, not a creatine effect

Key Takeaways

• This paper is a broad review of ADHD biology, not a creatine trial.
• The review centres dopamine and noradrenaline systems, while noting wider neurotransmitter and brain-network involvement.
• Genetic findings support a highly polygenic model rather than a single biological cause of ADHD.
• Neuroimaging and multi-omics results are informative but heterogeneous, limiting simple conclusions.
• For creatine users, the practical message is caution: promising brain-energy theories are not the same as proven ADHD benefits.
• Creatine monohydrate remains the most-studied form, but this paper does not provide dosing evidence for ADHD.

What this review actually found about ADHD biology

This paper’s core message is straightforward: ADHD does not appear to stem from one single biological defect. Instead, the review argues that ADHD reflects a complex mix of altered neurotransmission, differences in brain structure and function, highly polygenic genetic influences, and environmental factors that affect both onset and long-term course.

The authors place particular emphasis on dopaminergic and noradrenergic systems, which fits long-standing ADHD research and the known mechanisms of common medications. But the review also stresses that other neurotransmitter pathways likely contribute, and that these systems interact rather than operate in isolation.

On neuroimaging, the paper points to structural and functional differences in areas including the frontal cortex and subcortical regions. Crucially, it also notes that imaging findings remain heterogeneous. That matters because heterogeneous evidence can be biologically meaningful without being precise enough to support simple consumer claims.

On genetics, the review describes ADHD as highly polygenic, with both common and rare variants affecting synaptic transmission, neuronal development, and regulatory processes. It also highlights shared genetic influences between ADHD and a range of psychological, social, and somatic traits.

For readers interested in creatine, the big takeaway is not that creatine works or does not work for ADHD. It is that the underlying condition is biologically complex enough that any supplement claim needs direct evidence in people with ADHD, not just a plausible mechanism tied to brain energy or neurotransmitters.

Why this matters if you take or are considering creatine

This review never tests creatine, but it is still relevant to the creatine conversation because ADHD is often discussed online in ways that jump too quickly from mechanism to recommendation. A paper like this is a useful corrective.

Creatine is best known for helping increase muscle phosphocreatine stores and supporting high-intensity performance. It is also studied in some brain-health contexts because the creatine-phosphocreatine system helps buffer cellular energy demand. That can make ADHD seem like a natural target for supplementation. But this review shows why that leap is not enough.

• ADHD biology is multi-layered: neurotransmitters, brain circuits, genetics, and environment all matter.
• Findings are heterogeneous: not every person with ADHD shows the same biological profile.
• Mechanistic plausibility is not clinical proof: a supplement can make theoretical sense and still fail to improve symptoms in practice.

So where does that leave creatine users? If you already use creatine monohydrate for training, this paper does not suggest you should stop. The broader creatine literature still supports it as a well-studied sports supplement, especially in monohydrate form. Our creatine guides cover the basics, and the creatine dosage calculator can help with standard sports-nutrition use.

But if you are specifically hoping creatine will treat ADHD symptoms, this review does not provide that evidence. It instead reinforces the need for targeted human trials with clear outcomes, proper controls, and enough participants to detect meaningful effects.

This is a narrative review, not a clinical trial

One of the most important points for readers is the study design. This paper is a comprehensive overview of the biological foundations of ADHD. In practice, that means it synthesizes evidence from multiple research areas, including neurochemistry, pharmacology, genetics, neuroimaging, and multi-omics. It is not an intervention study, and it does not randomize people to creatine or placebo.

That design has clear strengths. Reviews can connect findings across fields and show how separate lines of evidence fit together. In ADHD, that matters because no single method fully explains the condition. A well-executed review can therefore be more useful for big-picture understanding than any one small experiment.

But the design also creates limitations:

• It cannot establish whether creatine improves ADHD symptoms.
• It cannot provide a dosing protocol for ADHD.
• It depends on the quality and consistency of the studies it summarizes.
• It may describe associations and biological patterns that are real but not yet clinically actionable.

The abstract also signals another key limitation: the evidence base is heterogeneous, and larger, more integrative studies are still needed. That is especially important in fields like imaging and omics, where methods, populations, and outcome definitions can differ substantially across studies.

In journalistic terms, this is a map of the territory, not a treatment verdict. It helps explain ADHD’s biological architecture. It does not settle supplement questions.

Where creatine evidence stands now, separate from this paper

Outside this review, creatine’s strongest evidence remains in exercise performance, training adaptation, and lean mass support, particularly with creatine monohydrate. Standard maintenance intake is commonly 3 to 5 g per day, and a typical loading approach is about 20 g per day split into 4 doses for 5 to 7 days. Those are mainstream sports-nutrition practices, not ADHD-specific recommendations.

The International Society of Sports Nutrition position stand remains one of the best summaries of creatine’s established use and safety profile in healthy populations. It also reinforces a crucial point for consumers: monohydrate is the most-studied form. See Kreider et al. (2017) and Antonio et al. (2021) for broader context.

What about brain and cognition? There is interest, and some lines of research suggest creatine may matter in certain neurological or cognitively demanding settings. But that evidence is not the same as demonstrating benefit for ADHD specifically. This new review underlines why precision matters: a biologically plausible nutrient is not automatically an evidence-based ADHD intervention.

If your main goal is gym performance, standard creatine use remains reasonable, and our best creatine rankings, creatine brand reviews, and creatine product catalog can help you compare options. If your goal is ADHD symptom management, the evidence bar should be much higher.

Practical takeaways for people with ADHD who are thinking about creatine

If you have ADHD and are considering creatine, the most practical message from this review is to separate general creatine use from ADHD treatment expectations.

1. Do not treat this paper as proof of benefit. It does not test creatine and does not report symptom changes.
2. Keep expectations grounded. The review shows ADHD involves multiple biological systems, so it is unlikely that one supplement will be a universal fix.
3. If you use creatine for training, use standard evidence-based practices. Creatine monohydrate is the best-supported choice; avoid assuming expensive alternative forms are better.
4. Talk to a clinician if ADHD symptom control is the goal. That is especially true if you take medication or are evaluating a broader treatment plan.

It is also worth remembering that ADHD has important behavioural, educational, and environmental dimensions. This review explicitly notes that environmental factors can influence both onset and prognosis, alongside gene-environment correlations and interactions. In other words, biology matters, but it is not the whole story.

For supplement buyers, that means avoiding simplistic marketing. A mechanistic pitch about brain energy, dopamine, or focus can sound impressive while still falling short of meaningful clinical evidence. This paper is a strong reminder to ask the hard question: has this actually been shown in people with ADHD?

How this review fits the bigger evidence picture

As a news item, this paper matters less because it changes creatine practice today and more because it sharpens the standards for future claims. The review’s framing of ADHD as complex, highly polygenic, and multi-level pushes back against one-size-fits-all biological narratives.

That has two implications. First, it helps explain why ADHD research often produces mixed findings across imaging, genetics, and biomarker studies. Second, it suggests that any future creatine research in ADHD should be designed carefully, ideally with enough participants, clear subtype or phenotype definitions, relevant symptom outcomes, and attention to comorbidities and baseline diet.

The paper also highlights the translational potential of multi-omics while stressing that larger and more integrative studies are still needed. That is an important nuance. “Translational potential” means there may eventually be clinically useful applications, not that such applications already exist.

For readers of Creatine Canada, the broader lesson is consistent with good supplement literacy: use the strongest evidence for the question you are actually asking. If the question is performance, creatine has a mature evidence base. If the question is ADHD symptom improvement, this review shows why the biology is intriguing but the answer remains unproven.

That distinction is how evidence-based coverage stays accurate and useful.

Bottom line

This new Bioscience Reports review provides a broad, up-to-date synthesis of ADHD biology and concludes that the condition spans neurotransmitter changes, heterogeneous brain findings, polygenic risk, and environmental influences. That is valuable science news.

For creatine readers, the practical conclusion is even simpler: this paper does not show that creatine helps ADHD. What it does show is why claims in that area should be held to a high standard. ADHD is biologically complex, and plausible mechanisms alone are not enough.

If you use creatine for training, standard creatine monohydrate practice remains supported by the wider literature. If you are considering creatine specifically for ADHD-related benefits, the responsible interpretation is to wait for direct, condition-specific clinical evidence rather than relying on theory, anecdotes, or marketing.

In short, this review maps the problem clearly. It does not yet supply a creatine solution.

What this ADHD review means for creatine users

• 0 creatine trials in this paper — This source is a biological review, not a creatine intervention study.
• 2 main neurotransmitter systems highlighted — The review primarily emphasizes dopaminergic and noradrenergic pathways.
• 3-5 g/day standard creatine maintenance — Mainstream sports-nutrition guidance, not an ADHD-specific dose.
• ~20 g/day common creatine loading protocol — Typically split into 4 doses for 5-7 days; again, not ADHD-specific.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN